What happened

INTA fell 12.87% on 6.8x volume after Q2 FY2026 earnings (Feb 3), despite beating on revenue ($140.2M vs $138.2M est) and EPS ($0.33 vs $0.26 est). Stock hit RSI 13.8, 1% of 52-week range.

The selloff trigger: Q3 operating income guided $23.1-24.1M, down from Q2's $27.7M.

Why it matters

The market reacted to sequential margin compression without parsing the context:

Full year guidance maintained. FY2026 operating income still $99.9-103.9M. The Q3 hit is front-loaded, not structural.

The spend has a destination. CFO Morton explicitly flagged "incremental spend targeted marketing campaigns upcoming product showcase Intapp Amplify, as well as targeted investments rate pace delivery on AI suite offerings."

Amplify is imminent. CEO Hall called it "Single largest release ever. Most consequential release...works two years." Event in ≈3 weeks (mid-February 2026).

The thesis

INTA is a quality compression beneficiary - as professional services firms use fewer, better professionals, each needs better AI-powered workflow tools. CEO confirmed this on the call: "Assist most successfully getting much richer, better, clearer answers compliant way more comprehensively all people... capability difficult imagine doing totally human-powered world."

124% cloud NRR, $200M fresh buyback authorization at depressed prices (15%+ of float at current price), Microsoft now co-investing Azure dollars (not just co-selling) on deals.

Analyst consensus: $57.88 mean target (+97.5% upside). Four consecutive earnings beats (Q1-Q4: +19%, +18%, +24%, +27% surprise).

What could be wrong

  • Guidance skepticism justified? Barclays (Underweight, $46) has been bearish since Jul 2025, citing deceleration risk. If Q3 investment spend doesn't translate to Amplify success, full-year guidance may get cut.

  • Valuation premium unwinding. INTA traded at 7.5x forward revenue in May 2025 (per SA coverage). Vertical SaaS multiples compressing across the sector.

  • Insider selling pattern. CEO Hall had small-lot sales in Dec 2025 (≈$750K combined). Not alarming given conversions but worth noting.

  • Factor exposure. 64.6% idio variance (idio vol 36.9% vs total vol 45.9%) - below the 75% Paleologo target. ≈35% of variance explained by market/sector factors. Tech sector rotation could drag recovery regardless of company fundamentals.

What we don't know

  1. Amplify content. "Most consequential release" is management hype until we see the product. Could be vaporware, could be real.

  2. AI monetization model. Hall discussed "consumption-based" pricing exploration but no specifics. If AI features don't monetize, NRR expansion slows.

  3. Why this reaction magnitude. Down 13% on beat/raise with maintained full-year seems overdone. Either market knows something (leaky guidance, institutional unwind) or this is mispricing.

Setup

Technical extreme (RSI 13.8) + fundamental beat + maintained guidance + imminent catalyst (Amplify mid-Feb) + aggressive buyback ($200M) + quality compression thesis validated by CEO.

The question is whether Q3 margin compression foreshadows something structural, or whether market overreacted to headline without reading the full guidance.

Near-term catalyst: Amplify event ~Feb 17-21 window. If "most consequential release ever" delivers, stock re-rates from extreme oversold. If it disappoints, Q3 guidance skepticism validated.